eISSN: 1644-4124
ISSN: 1426-3912
Central European Journal of Immunology
Current issue Archive Manuscripts accepted About the journal Special Issues Editorial board Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
Search
3/2014
vol. 39
 
Share:
Send email
Share:
abstract:

Experimental immunology
Effects of sufentanil on human gastric cancer cell line SGC-7901 in vitro

Weidong Wu
,
Ningxian Wei
,
Chun-nan Jiang
,
Suyang Cui
,
Jintao Yuan

(Centr Eur J Immunol 2014; 39 (3): 299-305)
DOI: https://doi.org/10.5114/ceji.2014.45939
Online publish date: 2014/10/14
View full text Get citation
 
PlumX metrics:
Sufentanil is a new kind of opioid analgesic and acts on µ opioid receptor. In this study, we aim to investigate the effects of sufentanil on gastric cancer cell line SGC-7901, after being exposed to different concentrations of sufentanil. Gastric cancer cells were exposed to sufentanil for a predetermined time at concentrations of 0, 0.5, 5, 50 and 500 nmol/l, respectively. Cell viability at different time points after exposure to sufentanil was tested by CCK-8 assay. FDA-PI staining was used to observe membrane integrity of gastric cancer SGC7901 cells. The apoptosis of gastric cancer cells was analyzed by Annexin V-FITC/PI Flow Cytometry and the changes of the cell cycle was determined by a detection kit. As a result, cell viability decreased in a dose- and time-dependent manner. Furthermore, with the concentration of sufentanil increased, the proportion of dead and apoptotic SGC-7901 cells increased, and more cells were arrested in G2/M phase. In a word, sufentanil can inhibit the cell viability and induce the apoptosis of gastric cancer SGC-7901 cells in vitro.
keywords:

sufentanil, gastric cancer cell, cell cycle arrest, apoptosis
Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2024 Termedia Sp. z o.o.
Developed by Bentus.